Strong sales growth for Elscint's magnetic resonance imaging (MRI) product line
This article was originally published in Clinica
Israeli company Elscint's second-quarter sales were $75.4 million, up 14%. The company attributes this to increased sales of its MRI product line, which accounted for 30% of total sales, compared with 8% for the same period in the previous year. The company notes, however, that sales were hindered by the continued sluggish US market and a delay in the commercial supply of SeleCT, its spiral CT, which was introduced in December last year. In addition, previously agreed sales of equipment to China have been delayed.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.